BRIDGE 2-Part LIVE Webinar Series - November 26th & December 3rd, 2026 | 8:00-9:30 p.m. ET

Translating Global Insights into Canadian T1D Screening Practice

Broadcast Date

From early detection to emerging therapies.

Join leading Canadian and international experts in exploring practical approaches to Type 1 Diabetes (T1D) screening, early detection, and emerging therapies, including teplizumab.

The series will feature expert perspectives, international insights, and practical considerations for T1D care within the Canadian healthcare setting.

Register for both sessions 

Registration will automatically enroll you in both webinar sessions.

SESSION 01 · NOVEMBER 26

T1D Screening: From Evidence to Practice

Thursday, November 26, 2026
8:00–9:30 p.m. ET

Learning objectives

By the end of this program, you will be able to:

  1. Identify individuals who may benefit from pre-clinical T1D screening and explain the clinical rationale, benefits, and limitations of early detection.
  2. Interpret T1D screening results and apply current approaches to confirmatory testing, staging, monitoring, and referral.
  3. Apply learnings from international screening programs and available Canadian resources to develop practical approaches to T1D screening, referral, and follow-up.
  4. Discuss emerging screening approaches and their potential implications for the future of T1D care.

Faculty

Alice Cheng
MD, FRCPC
Endocrinologist
Toronto, ON

Akshay Jain
MD, FRCPC, FACE, ECNU, DABIM, DABOM
Endocrinologist
Surrey, BC

James Stainer
RN, CDE, CPT, BScN
Registered Nurse
Toronto, ON

Register for November 26 → 

SESSION 02 · DECEMBER 3

Advancing T1D Care: Teplizumab in Practice

Thursday, December 3, 2026
8:00–9:30 p.m. ET

Learning objectives

By the end of this program, you will be able to:

  1. Summarize the evidence and mechanism of action of emerging T1D therapies, including teplizumab.
  2. Compare international and Canadian clinical experience with teplizumab, including patient identification and selection.
  3. Describe practical considerations for teplizumab administration, monitoring, and patient management.
  4. Apply practical, real-world lessons to support the implementation of teplizumab in the Canadian healthcare setting.

Faculty

Bruce A. Perkins
MD, MPH, FRCPC
Endocrinologist
Toronto, ON

Kimber Simmons
MD, MS
Pediatric Endocrinologist
Aurora, CO, USA

Michael Tsoukas
MD, FRCPC
Endocrinologist
Montréal, QC

Register for December 3 → 

Questions? Contact t1dwebinars [at] eocihealth.com (t1dwebinars[at]eocihealth[dot]com).